Modulus Therapeutics, a Seattle-dependent cellular remedy firm spun out of the Allen Institute of Artificial Intelligence (AI2), introduced $3.5 million in seed funding.
The organization combines laboratory research with device studying to engineer immune cells with enhanced anti-tumor powers. Modulus focuses on making performance-maximizing genetic adjustments in natural killer (NK) cells, an up-and-coming immune mobile variety in the cell treatment discipline.
Modulus is creating a system that could likely present early cell merchandise candidates to far more mature cellular treatment providers for more screening.
Seattle is known